Teva Win on Three Migraine Drug Patents, Losses on Six Upheld

Sterne, Kessler, Goldstein & Fox was mentioned as representing Teva Pharmaceuticals in the article “Teva Win on Three Migraine Drug Patents, Losses on Six Upheld,” published by Bloomberg Law. From the article:

“The Federal Circuit upheld three Teva Pharmaceutical Industries Ltd. patents on its Ajovy migraine drug, but found six others were properly invalidated.

Eli Lilly & Co., which makes the competing drug Emgality, had challenged the nine patents at the Patent Trial and Appeal Board after Teva sued for infringement. The U.S. Court of Appeals for the Federal Circuit affirmed the board’s rulings Monday in three separate opinions.”